{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:18:13Z","timestamp":1762899493819,"version":"3.37.3"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate our experience with metastasectomy following partial response or stable disease after treatment with high\u2010dose interleukin\u20102 (HD IL\u20102).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 305 patients with metastatic renal cell carcinoma or melanoma treated with HD IL\u20102 over a 12\u2010year period were reviewed. Age, objective response, and overall survival data were evaluated using standard RECIST criteria and Kaplan\u2010Meier estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The average age was 55.3 years (range, 15\u201085) and 245 (80.3%) patients had melanoma and 60 (19.7%) had renal cell carcinoma. The objective response rate to IL\u20102 for all patients was 13.6% and median survival was 16.8 months. Complete follow\u2010up data were available for 236 patients with 147 (62.3%) progressing after treatment and 8 (3.3%) with a complete response. Incomplete responses were seen in 81 (34.3%) patients, including 57 (24.2%) patients with stable disease and 24 (10.1%) with partial responses. Of these 81 incomplete responders, 15 (18.5%) underwent subsequent metastasectomy. Patients without surgery had overall survival of 38.2 months and median survival has not yet been reached in those who underwent metastasectomy (<jats:italic>P<\/jats:italic>\u2009=\u20090.026).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The data support prospective evaluation of metastasectomy following incomplete therapeutic responses to immunotherapy and defines a new role for surgical resection following IL\u20102 and perhaps other immunotherapy regimens.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.24916","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T15:59:04Z","timestamp":1511366344000},"page":"572-578","source":"Crossref","is-referenced-by-count":3,"title":["Metastasectomy following incomplete response to high\u2010dose interleukin\u20102"],"prefix":"10.1002","volume":"117","author":[{"given":"Tasha","family":"Hughes","sequence":"first","affiliation":[{"name":"Department of General Surgery Rush University Medical Center Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Broucek","sequence":"additional","affiliation":[{"name":"Department of General Surgery Rush University Medical Center Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Iodice","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery Columbia University New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen K.","family":"Bommareddy","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology Rutgers University New Brunswick New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjib","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of General Surgery Rush University Medical Center Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-4166","authenticated-orcid":false,"given":"Howard L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology Rutgers University New Brunswick New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.05.010"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824"},{"key":"e_1_2_6_4_1","article-title":"Systemic therapy following metastasectomy for renal cell carcinoma: using insights from other clinical settings to address unanswered questions","author":"Appleman LJ","year":"2017","journal-title":"Urol Oncol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0459"},{"key":"e_1_2_6_6_1","first-page":"S11","article-title":"High\u2010dose recombinant interleukin\u20102 therapy in patients with metastatic melanoma: long\u2010term survival update","volume":"6","author":"Atkins MB","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"e_1_2_6_8_1","first-page":"S55","article-title":"Long\u2010term survival update for high\u2010dose recombinant interleukin\u20102 in patients with renal cell carcinoma","volume":"6","author":"Fisher RI","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2007.07.011"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003634"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1992.01420110091018"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1385\/IR:36:1:13"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-13"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1652-6"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2006.08.065"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2197-y"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000076"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9836-y"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.136.8.950"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25836"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000019849"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.05.006"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603327"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31824bc981"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08490.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70222-0"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.05.014"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.032"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3660"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603391"},{"key":"e_1_2_6_32_1","first-page":"43","article-title":"Effects of a preoperative course of interleukin\u20102 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study","volume":"159","author":"Brivio F","year":"1993","journal-title":"Eur J Surg"},{"key":"e_1_2_6_33_1","first-page":"1872","article-title":"Phase\u2010II randomized study of preoperative IL\u20102 administration in radically operable gastric cancer patients","volume":"51","author":"Romano F","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_6_34_1","first-page":"1951","article-title":"Free\u2010from\u2010progression period and overall short preoperative immunotherapy with IL\u20102 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery","volume":"28","author":"Caprotti R","year":"2008","journal-title":"Anticancer Res"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(98)00024-5"},{"key":"e_1_2_6_36_1","first-page":"303","article-title":"Phase I\u2010II randomized study on prehepatectomy recombinant interleukin\u20102 immunotherapy in patients with metastatic carcinoma of the colon and rectum","volume":"181","author":"Elias D","year":"1995","journal-title":"J Am Coll Surg"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4804(86)90193-9"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4804(90)90190-D"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030590"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.24916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.24916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T04:10:40Z","timestamp":1694319040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.24916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/jso.24916"],"URL":"https:\/\/doi.org\/10.1002\/jso.24916","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"type":"print","value":"0022-4790"},{"type":"electronic","value":"1096-9098"}],"subject":[],"published":{"date-parts":[[2017,11,22]]}}}